Drug intelligence / Profile preview

Liraglutide + Orlistat Combination

Development stage
Phase 4
Lead developer
Novo Nordisk
Modality
Small Molecules, Peptides
Administration
Subcutaneous, Oral
01

Overview

This entry describes the potential concurrent use of two individual weight loss medications: liraglutide and orlistat. Liraglutide (brand names Saxenda, Victoza) is a GLP-1 receptor agonist that works by mimicking an intestinal hormone to increase feelings of fullness and decrease hunger signals[1][7]. Orlistat (brand names Xenical, Alli) is a lipase inhibitor that blocks the digestion and absorption of about one-third of dietary fat in the gut[1][5]. While each medication is FDA-approved for weight management and has demonstrated individual efficacy[2][3][7][8], the provided information does not detail specific clinical trials or official recommendations for their combined use[5]. Theoretically, their different mechanisms of action (appetite control vs. fat absorption inhibition) could be complementary[5]. However, concurrent use may amplify common gastrointestinal side effects associated with each drug, such as nausea, vomiting, diarrhea (liraglutide) and oily discharge, increased defecation, and fatty stools (orlistat)[1][5][7]. Orlistat use requires adherence to a low-fat diet to manage these side effects[5]. Any consideration of using these medications together would require careful medical supervision.

02

Targets

GLP1R (GLP-1R)LIPF (Gastric lipase)GehA (Triacylglycerol lipase GehA)

Beyond the preview

Go deeper on Liraglutide + Orlistat Combination.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Liraglutide + Orlistat Combination.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call